

A New Ursane-type Triterpenoid from *Salvia santolinifolia*

Zaheer AHMAD¹, Sajid MEHMOOD³, Rehana IFZAL^{1*}, Abdul MALIK²,
Nighat AFZA³, Mohammad ASHRAF⁴ and Erum JAHAN²

¹Department of Chemistry, University of Karachi, 75270, Karachi-PAKISTAN
e-mail: rehanaifzal@gmail.com

²International Centre for Chemical Sciences, HEJ Research Institute of Chemistry,
University of Karachi, 75270, Karachi-PAKISTAN

³Pharmaceutical Research Centre, PCSIR Laboratories Complex, 75280, Karachi-PAKISTAN

⁴Department of Pharmacy, Faculty of Pharmacy and Alternative Medicine,
The Islamia University of Bahawalpur, Bahawalpur-PAKISTAN

Received 15.03.2007

Santolinoic acid (**1**), a new ursane-type triterpene was isolated from the chloroform soluble fraction of *Salvia santolinifolia*. Its structure was established as 2 α ,3 β ,9 α -trihydroxyurs-12-en-28-oic acid on the basis of spectroscopic analysis, including high resolution mass spectroscopy, and 1- and 2-dimensional NMR techniques. The compound (**1**) showed inhibitory activity against the enzymes acetylcholinesterase and butyrylcholinesterase.

Key Words: *Salvia santolinifolia*, Labiatae, triterpenoid, enzyme inhibition.

Introduction

The genus *Salvia* belongs to the family Labiatae, which comprises 24 species. It is characterized by branched herbs and shrubs that are distributed in Pakistan, India, and Afghanistan. *Salvia santolinifolia* Boiss. is a branched, scabrid, and hispid straggling undershrub occurring in Peshawar, Baluchistan, and Karachi. Various species of this genus are widely used for treatment of coronary heart diseases, particularly angina pectoris, amenorrhea, dysmenorrhea, and insomnia. Most species, including *S. santolinifolia*, additionally possess antiseptic, carminative, diuretic, hemostatic, and spasmolytic properties.^{1–3}

Previously, a variety of compounds, including diterpenes, aromatic ethers, phenolic glycosides, triterpenes, and abietane type pigments, have been reported from this plant.⁴ The methanolic extract of this plant revealed a strong toxicity in the brine shrimp lethality test.^{5,6} During a search for new bioactive compounds from indigenous medicinal plants, we isolated santolinoic acid (**1**), as well as oleanolic acid (**2**) and 1 β , 3 β , 23-trihydroxyolean-12-en-28-oic acid (**3**), from the chloroform-soluble fraction, which is reported for the first time from this plant source.

*Corresponding author

Experimental

General and instrumentation

The $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, HMQC, and HMBC spectra were recorded on Bruker spectrometers, operating at 400 MHz for $^1\text{H-NMR}$ and 100.6 MHz for $^{13}\text{C-NMR}$. EIMS and HR-FAB-MS were recorded on a Jeol JMS-HX-110 with a data system and on JMS-DA 500 mass spectrometers. IR spectra were recorded on a 460 Shimadzu spectrometer (ν in cm^{-1}). Optical rotations were measured on a JASCO DIP-360 polarimeter. Visualization of the TLC plates was achieved under UV at 254 and 366 nm, and by spraying with ceric sulfate reagent solution (with heating). For TLC, pre-coated aluminum sheets, silica gel 60 F₂₅₄ (20 × 20 cm, 0.2 mm thick; Merck), and for column silica gel (230-400 mesh) were used. The chemical shift values are reported in ppm (δ) units and the coupling constants (J) are in Hz. For enzyme inhibition assay, all chemicals and butyrylcholinesterase were purchased from Sigma (USA).

Plant material

Whole plants of *Salvia santolinifolia* Boiss. (24 kg) were collected from Karachi (Pakistan) in July 2002 and identified by Dr. Surriya Khatoon, Plant Taxonomist, Department of Botany, University of Karachi, where a voucher specimen (LS 831) is deposited.

Extraction and isolation

Salvia santolinifolia plants were shade dried, ground, and extracted 3 times with ethanol. The combined ethanolic extract was partitioned between hexane and MeOH. The MeOH fraction was further partitioned with CHCl_3 and then with EtOAc. The CHCl_3 fraction (35 g) was subjected to column chromatography over silica gel eluting with hexane- CHCl_3 , CHCl_3 , CHCl_3 -MeOH, and MeOH, in increasing order of polarity. The fractions that were obtained from the column through elution with CHCl_3 -MeOH (9.5:0.5) were a mixture of 2 components, which could be resolved through preparative TLC using a solvent system (CHCl_3 : MeOH; 9.2:0.8) to obtain oleanolic acid (**2**) (18 mg) and 1β , 3β , 23-trihydroxyolean-12-en-28-oic acid (**3**) (20 mg), respectively.

The identity of these compounds was confirmed through comparison of their physical and spectral data with those reported in the literature.^{7,8}

The fraction obtained from CHCl_3 -MeOH (9.6:0.4) was subjected to column chromatography over silica gel using a solvent system CHCl_3 -MeOH (9.3:0.7) and final purification was performed by preparative TLC using a solvent system CHCl_3 -MeOH (8.8:1.2) to afford the new triterpene, santolinoic acid (**1**) (28 mg).

Santolinoic Acid (1)

Santolinoic acid (**1**) was obtained as a colorless amorphous solid. $[\alpha]_D^{26} - 78.2^\circ$ ($c = 0.064$, MeOH) IR (KBr) ν_{max} cm^{-1} : 3450, 1700, 1655. $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ (Table 1). HREIMS $[\text{M}^+]$ m/z 488.3490 (calcd. for $\text{C}_{30}\text{H}_{48}\text{O}_5$: 488.3501). EIMS m/z (rel. int. %): 488 (10), 456 (28.5), 442 (5.0), 396 (8.4), 248 (100), 203 (82), 187 (33.8), 149 (15), 105 (44) 69 (41.3), 55 (52.6).

Acetylation of santolinoic acid (**1**)

Compound **1** (14.0 mg) was acetylated with Ac₂O (2 mL) in pyridine (2 mL) at room temperature for 24 h. Usual workup provided the corresponding acetyl derivative (**1a**). Amorphous solid [α]_D²⁶ – 45.4° (c = 0.058, MeOH): IR (KBr) ν_{max} cm⁻¹: 3410, 1720, 1660. ¹H-NMR (400 MHz, CD₃OD) δ : 0.79 (3H, s, Me-24), 0.98 (3H, d, *J* = 5.8 Hz, H-29), 1.09 (3H, s, Me-23), 1.11 (3H, d, *J* = 6.7 Hz, H-30), 1.18 (3H, s, Me-25), 1.29 (3H, s, Me-27), δ 2.03 (6H, s, 2xOAc), 3.27 (1H, d, *J* = 9.5 Hz, H-3), 3.97 (1H, ddd, *J* = 10.8, 9.5, 4.0 Hz, H-2), 5.25 (1H, t, *J* = 3.4 Hz, H-12). HR-FAB-MS [M⁺] *m/z* 572.3761 (calcd. for C₃₄H₅₂O₇: 572.3713). EIMS *m/z* (rel. int %): 440 (5.8), 375 (10), 248 (100), 219 (18), 187 (33).

Methylation of **1a**

To an ethereal solution of **1a** (10 mg) was added freshly prepared CH₂N₂ in excess, followed by storage at room temperature overnight. Usual workup of the reaction mixture afforded **1b**, which crystallized in white needles from concentrated methanolic solution in the cold. ¹H-NMR (500 MHz, CD₃OD) δ : 0.78 (3H, s, Me-24), 0.92 (3H, d, *J* = 6.7 Hz, H-30), 1.01 (3H, d, *J* = 5.8 Hz, H-29), 1.03 (3H, s, Me-23), 1.15 (3H, s, Me-25), 1.31 (3H, s, Me-27), 2.02 (6H, s, 2x OAc) 3.12 (3H, s, OCH₃), 3.29 (1H, d, *J* = 9.5 Hz, H-3), 3.99 (1H, ddd, *J* = 10.8, 9.5, 4.0 Hz, H-2), 5.25 (1H, t, *J* = 3.4 Hz, H-12). HR-FAB-MS [M⁺] *m/z*: 586.3895 (calcd. for C₃₅H₅₄O₇: 586.3869) EIMS *m/z* (rel. int %): 442 (5), 248 (100), 187 (33).

Cholinesterase inhibition assay

The enzyme activities were determined by a modified method of Ellman et al.^{9,10} Electric eel acetylcholinesterase (AChE, 3.1.1.7), horse serum butyrylcholinesterase (BChE, 3.1.1.8), acetylthiocholine iodide, butyrylthiocholine chloride, 5,5'-dithiobis [2-nitrobenzoic acid (DTNB), and galanthamine were purchased from Sigma (USA). The reaction mixture contained 150 μ L of phosphate buffer, pH 8.0 (100 mM), 10 μ L of DTNB (0.25 mM), 10 μ L of test compound in ethanol, and 20 μ L of enzyme. The contents were mixed and pre-incubated at 25 °C for 10 min. The reaction was initiated by the addition of 10 μ L of the substrate (30 mM) of the respective enzyme. The hydrolysis of the substrate was measured at 412 nm after 15 min by the formation of the yellow 5-thio-2-nitrobenzoate anion. All the reactions were performed in triplicate on a Spectra Max 384 Plus 96-well plate reader (Molecular Devices, USA). The IC₅₀ values were calculated using the EZ-Fit Enzyme Kinetics program (Perrella Scientific Inc., Amherst, USA).

Results and Discussion

The IR spectrum of **1** displayed absorptions for hydroxyl groups (3450 cm⁻¹), acid carbonyl (1700 cm⁻¹), and a double bond (1655 cm⁻¹).¹¹ The HREIMS showed [M⁺] a peak at *m/z* 488.3490 corresponding to the molecular formula C₃₀H₄₈O₅ (calcd. for C₃₀H₄₈O₅, 488.3501). Acetylation of **1** provided diacetate (**1a**), which still showed the hydroxyl absorption in its IR spectrum, confirming the presence of one or more tertiary hydroxyls. Methylation of **1** afforded the monomethyl ester (**1b**), confirming the presence of one carboxyl group. In EIMS, the peaks at *m/z* 240.1720 (C₁₄H₂₄O₃, 240.1725) and 248.1768 (C₁₆H₂₄O₂, 248.1776) could be assigned to the fragments of the A/B rings and D/E rings formed by retro-Diels-Alder

fragmentation of the C-ring. These fragment ions confirmed the presence of 2 oxygen functionalities in rings D/E and the remaining 3 oxygen functionalities in rings A/B. The fragment at 248, being common to that of ursolic acid, allowed us to assign the carboxylic group at the angular C-17 position.⁸ This was further authenticated by a peak at m/z 203 due to the loss of the carboxylic group from the fragment ion at m/z 248. In addition, the ¹³C-NMR spectrum showed signals for 7 methyls, 8 methylenes, 7 methines, and 8 quaternary carbons, together with 1 carboxyl group at δ 181.0. While the signals of olefinic carbons were observed at δ 138.2 and δ 128.5, respectively, 2 oxymethine carbons were observed at δ 83.4 and δ 68.4, while a downfield quaternary carbon at δ 72.9 indicated the presence of a tertiary hydroxyl group. The ¹H-NMR spectrum showed a trisubstituted double bond at δ 5.25 (t, J = 3.4 Hz), and 2 oxymethine protons at δ 3.61 (1H, ddd, J = 10.8, 9.5, 4.0 Hz) and δ 2.92 (1H, d, J = 9.5 Hz). In addition, 5 tertiary methyls were observed as singlets at δ 1.31, 1.16, 1.03, 0.99, and 0.78, while doublets of 2 additional secondary methyls were observed at δ 1.00 (3H, d, J = 5.8 Hz) and 0.91 (3H, d, J = 6.7 Hz). The above data was consistent with an ursane-type triterpene carrying a double bond at Δ^{12} .¹²

Acetylation of **1** to the corresponding diacetyl derivative (**1a**) showed that 2 out of the 3 remaining oxygens are accounted for by secondary hydroxyls, providing evidence for a tertiary hydroxyl. It was supported by the presence of the corresponding carbons signals at δ 68.4 (d), 83.4 (d), and 72.9 (s) in the ¹³C-NMR spectrum. As the mass fragmentation pattern of **1** indicated that all the hydroxyl groups were present in rings A and/or B, their positions at C-2, C-3, and C-9 were conclusively established through HMQC and HMBC experiments in which H-2 (δ 3.61) showed ²J correlation to C-3 (δ 83.4) and ³J to C-4 (δ 41.1), while H-3 (δ 2.92) showed ²J correlation to C-2 (δ 68.4) and C-4 (δ 41.1), and ³J correlation to C-5 (δ 53.1), C-23 (δ 28.3), and C-24 (δ 16.4). The remaining tertiary hydroxyl group at C-9 could further be confirmed by HMBC experiments in which Me-25 and Me-26 (δ 1.16, 1.31) showed ³J correlations to C-9 (δ 72.9) supported by ³J correlation of H-12 (δ 5.25) to C-9 (δ 72.9).

The oxymethine proton at δ 2.92 showed ¹H-¹H correlations to the oxymethine proton at δ 3.61, while the latter also showed further ¹H-¹H correlation with 2 other protons. This allowed us to assign the hydroxyl groups to the C-2 and C-3 positions. The ¹H-NMR spectrum showed ddd at δ 3.61 ($J_{a,a}$ = 10.8, 9.5 Hz and $J_{a,e}$ = 4.0 Hz) and a doublet at δ 2.92 ($J_{a,a}$ = 9.5 Hz) for H-2 and H-3, allowing us to assign α and equatorial configuration for OH at 2-position, and β and equatorial configuration for OH at 3-position. The α configuration was assigned to OH-9 on the basis of biogenetic grounds and experimental results. Re-recording of the ¹H-NMR spectrum of **1a** in pyridine-*d*₅ did not show an anisotropic effect of OH-9 on Me-25 and Me-26, ruling out its β -configuration. The stereochemistry at C-2 and C-3 positions was precisely confirmed through 2D-NOESY correlations in which H-2 (δ 3.61) showed correlations with Me-24 (δ 0.78) and Me-25 (δ 1.16), Me-25 (δ 1.16) with Me-26 (δ 0.99), and H-3 (δ 2.92) with Me-23 (δ 1.03). Therefore, the structure of santolinoic acid (**1**) was elucidated as 2 α ,3 β ,9 α -trihydroxyurs-12-en-28-oic acid. Santolinoic acid (**1**) is the first naturally occurring ursane-type triterpene (from this plant source) with a hydroxyl function at C-9.

The inhibitory activity of santolinoic acid (**1**) (Table 2) observed in the present study revealed that this compound was active against the enzymes acetylcholinesterase and butyrylcholinesterase. Alzheimer's disease (AD) is a chronic neurological disorder, particularly affecting the elderly in developing countries. Despite the unknown etiology of AD, increasing the level of acetylcholine through AChE and BChE enzyme inhibition has been accepted as an effective treatment strategy for AD.¹³ Therefore, AChE and BChE

inhibitors have become good alternatives in the treatment of AD. The data showed that the newly isolated compound has moderate anti-cholinesterase activity.

Table 1. ¹H-NMR, ¹³C-NMR, and HMBC correlations for santolinoic acid (**1**).


1 (CD ₃ OD)			
Position	δ_C	δ_H	HMBC
1	46.1	0.88m	C-2, 10
2	68.4	3.61 ddd (10.8, 9.5, 4.0)*	C-3, 4
3	83.3	2.92 d (9.5)	C-2, 4, 5, 23, 24
4	41.1	-	
5	53.3	0.87 m	
6	18.3	1.34 m	
7	32.5	1.49 m	C-8, 5, 9, 14
8	39.0	-	
9	72.9	-	
10	37.9	-	-
11	25.3	1.91 m	
12	128.5	5.25 t (3.4)	C-9, 14
13	138.2	-	
14	39.8	-	
15	28.0	1.53 m	
16	23.5	1.62 m	
17	47.5	-	
18	55.0	2.58 d (6.64)	C-28
19	41.0	1.89 m	
20	47.0	1.99 m	
21	37.4	1.34 m	
22	25.3	1.66 m	
23	28.3	1.03 s	C-3, 5
24	16.4	0.78 s	C-3, 5
25	26.9	1.16 s	C-1, 5, 9
26	15.8	0.99 s	C-8, 9
27	24.1	1.31 s	C-13, 15
28	181.0	-	C-18
29	26.9	1.00 d (5.8)	C-19, 20
30	16.2	0.91 d (6.7)	C-20, 19, 21

**J*(Hz) in parentheses.

Table 2. AChE and BChE activity of santolinoic acid (**1**) (n = 3).

Compound	AChE Activity (μ M)	BChE Activity (μ M)
1	62.5 \pm 0.52	54.8 \pm 1.8
*Galanthamine	0.52 \pm 0.05	8.5 \pm 0.05

*Positive control.



- (1) R = R₁ = R₂ = OH, R₃ = H
 (1a) R = R₁ = OAc, R₂ = OH, R₃ = H
 (1b) R = R₁ = OAc, R₂ = OH, R₃ = CH₃

Figure 1. Structure of santolinoic acid (1).




Figure 2. Selected HMBC correlations of santolinoic acid (1).

References

1. S.I. Ali and Y.J. Nasir, *Flora of Pakistan*, Vol. 192, 200-202 (1990).
2. S.Y. Ryu, Z. No, S.H. Kim and J.W. Ahn, *Planta Medica* 63, 44-46 (1997).

3. A. Ulubelen, S. Oksuz, U. Kolak H. Birman and W. Voelter, **Planta Medica** **66**, 627-629 (2000).
4. A. Krishnamurthi, "The Wealth of India," CSIR, New Delhi, **Vol. IX**, 195-198 (1978).
5. G. Nagy, A. Dobos, G. Gunther, M. Yang, G. Blunden, T.A. Crabb and I. Mathe, **Planta Medica** **64**, 288-289 (1998).
6. B.N. Meyer, N.R. Ferrigni, J.E. Putnam, L.B. Jacobsen, D.E. Nichols and J.L. McLaughlin, **Planta Medica** **45**, 31-34 (1982).
7. R.B. Bates and D.J. Eckert, **J. Am. Chem. Soc.** **94**, 8258 (1972).
8. N. Riaz, I. Anis, A.U. Rehman, A. Malik, Z. Ahmed, P. Muhammad, S. Shujaat and A.U. Rahman, **Nat. Prod. Res.** **17**, 247-251 (2003).
9. G.L. Ellman, K.D. Courtney, V. Andres and R.M.A. Featherstone, **Biochem. Pharmacol.**, **7**, 88-95 (1961).
10. A.U. Rahman, S. Parveen, A. Khalid, A. Farooq and M.I. Choudhary, **Phytochemistry**, **58**, 963-968 (2001).
11. S. Siddiqui S. Begum, B.S. Siddiqui and F. Hafeez, **J. Nat. Prod.** **52**, 57-62 (1989).
12. H.T. Cheung and D.G. Williamson, **Tetrahedron**, **25**, 119 (1969).
13. S.E. Arnold and A. Kumar, **Med. Clin. Nort. Am.** **77**, 215-230 (1993).